|Videos|December 25, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Breakthrough Therapy Designation to Ficerafusp Alfa in Head and Neck Cancer
2
What Subcutaneous Keytruda Means for Patients With Melanoma
3
Breast Cancer Awareness Month Isn’t Always “Pink and Pretty”
4
The Gifts I Never Asked For: What Cancer Taught Me About What Really Matters
5
